Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Name: Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader
Professor of Cardiology
University of Adelaide
Consultant Cardiologist
Royal Adelaide Hospital
Adelaide, Australia